reports
Xianhe Co Ltd: 1 director
A director at Xianhe Co Ltd bought 910,400 shares at 19.820CNY and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Zhejiang Dibay Electric Co Ltd: 1 director
A director at Zhejiang Dibay Electric Co Ltd bought 25,800 shares at 13.960CNY and the significance rating of the trade was 37/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
MultiPlan Corp: 1 director
A director at MultiPlan Corp bought 160,000 shares at 0.600USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Athens International Airport S.A.: 1 director
A director at Athens International Airport S.A. bought 14,000 shares at 8.371EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
JP Morgan Chase & Co: 2 directors
Two Directors at JP Morgan Chase & Co sold 9,713 shares at between 200.640USD and 200.648USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Arthur J. Gallagher & Co: 2 directors
Two Directors at Arthur J. Gallagher & Co sold after exercising options/sold 27,771 shares at between 254.000USD and 255.922USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
Dong Hai JSC Of Bentre: 1 director
A director at Dong Hai JSC Of Bentre sold 909,500 shares at 0.000VND and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Gmo Tech Inc: 1 director
A director at Gmo Tech Inc sold 16,500 shares at 0.000JPY and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Anthony Dick
- Michael Foundoukidis
Stellantis : Un CMD pour un nouveau départ
Après un début d’année plus difficile qu’anticipé pour le constructeur, nous revenons ici davantage en détail sur les enjeux du prochain CMD (13/06) et nos attentes, qu’il s’agisse de leviers stratégiques encore sous-estimés ou de potentiel (significatif) de retour à l’actionnaire (près de 100%e de la capitalisation boursière actuelle d’ici 2030). Ainsi, il nous semble intéressant de revenir sur le titre (OC relevé à 30 €) en amont du CMD et des résultats semestriels alors que St...
- Markus Schmitt
ZF Friedrichshafen : We affirm credit opinion and recommendation
We confirm our Stable credit opinion and Neutral recommendation stance on ZF. - We are a bit tired of hearing and reading that ZF is over-levered. Yes, it has more leverage than peers, but even in the current state and when we add increased cash interest due to recent and coming refinancings it remains a positive levered free cash flow business. The only caveat is that in FY 24 it will spend an extra EUR 400m (offset by the Foxconn JV proceeds) on capex. Management is committed to ...
- Markus Schmitt
ZF Friedrichshafen : We affirm credit opinion and recommendation
We confirm our Stable credit opinion and Neutral recommendation stance on ZF. - We are a bit tired of hearing and reading that ZF is over-levered. Yes, it has more leverage than peers, but even in the current state and when we add increased cash interest due to recent and coming refinancings it remains a positive levered free cash flow business. The only caveat is that in FY 24 it will spend an extra EUR 400m (offset by the Foxconn JV proceeds) on capex. Management is committed to ...
- ABGSC IT Research
- Øystein Elton Lodgaard
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 1,000,000 shares at 1.020SGD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Metallus Inc: 2 directors
Two Directors at Metallus Inc sold 33,412 shares at between 24.000USD and 24.092USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
- Martin Marandon-Carlhian
- Stephane Houri
Arm Holdings plc : Arm remains the key vehicle to play the growing com...
>Outperform rating reiterated, target price increased to $ 130 (vs $ 110) - We did a recap with the company a few days after the release of its Q4 2023-24 results and came away with confirmation that Arm is set to continue to grow at an average of 20% per year over the next three years. Growth, as we wrote in our report initiating coverage of the stock, stems from an accelerated architecture complexification process, driven initially by the acceleration in significant...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-clas...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une c...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de construire des logiciels alimentés par l’IA afin d’accélérer le développement de médicaments et de proposer de nouveaux médicaments aux patients de manière plus efficace. Les trois équipes réuniront des données, des logiciels et des modèles adaptés pour développer d...
KKR Invests in Healthcare Revenue Solutions Provider Infinx
MUMBAI, India--(BUSINESS WIRE)-- KKR, a leading global investment firm, and Infinx Services Private Limited (“Infinx” or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a KKR-managed fund. Through this investment, KKR will leverage its extensive experience in the global healthcare and technology sectors to accelerate Infinx’s growth, expand the Company’s network, and support bolt-on acquisitions. Norwest Venture Partners, an existing shareholder, also participated in the transaction. This pr...
Nextensa : RESULTS ON Q1 2024
Nextensa : RESULTS ON Q1 2024 REGULATED INFORMATION Brussels, 21 May 2024, 07h30 NEXTENSA: RESULTS ON Q1 2024 HIGHLIGHTS INVESTMENT PROPERTIES • Despite some property sales in 2023 and 2024, rental income in Q1 is higher than in the same quarter last year.• Realisation of like-for-like rental growth of +4.5% in the first quarter of 2024 compared to 2023.• New lease agreement for the Moonar park with Regus (about 1,500 sqm), bringing the park’s lettings to about 80%.• In early February 2024, the retail property of approximately 4,200 m² on rue du Brill in Foetz, Luxem...
NEXTENSA: RÉSULTATS POUR LE Q1 2024
NEXTENSA: RÉSULTATS POUR LE Q1 2024 INFORMATION REGLEMENTEE Bruxelles, 21 mai 2024, 07h30 NEXTENSA: RÉSULTATS POUR LE Q1 2024 FAITS MARQUANTS IMMEUBLES DE PLACEMENT • Malgré la vente de certains actifs en 2023 et 2024, les revenus locatifs du premier trimestre sont supérieurs à ceux du même trimestre de l’année précédente.• Réalisation d’une croissance des loyers à périmètre constant de +4,5% au premier trimestre 2024 par rapport à 2023.• Nouveau contrat de location pour le campus de bureaux Moonar signé par Regus (+/- 1 500 m²), ce qui porte le taux de location du campus à...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.